EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Glucose‐lowering medication associated with weight loss may limit the progression of diabetic neuropathy in type 2 diabetes

Georgios Ponirakis iD, Ibrahim Al-Janahi, Einas Elgassim, Rawan Hussein, Ioannis N Petropoulos, Hoda Gad, Adnan Khan iD, Hadeel B Zaghloul, Mashhood A Siddique, Hamda Ali, Fatima F S Mohamed, Lina H M Ahmed und 16 weitere

Journal of the Peripheral Nervous System · 2024-12 · 29 (4) · 406-414

DOI: 10.1111/jns.12664 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of the Peripheral Nervous System, online erschienen am 22.10.2024. Verfasst von Georgios Ponirakis und 27 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Weill Cornell Medicine-Qatar, Qatar Foundation, Doha, Qatar. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Diabetic Neuropathies, Weight Loss, Hypoglycemic Agents. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Qatar National Research Fund.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aim

Obesity is a major risk factor for diabetic peripheral neuropathy (DPN) in type 2 diabetes (T2D). This study investigated the effect of glucose lowering medication associated with weight change on DPN.

Methods

Participants with T2D were grouped based on whether their glucose lowering medications were associated with weight gain (WG) or weight loss (WL). They underwent clinical, metabolic testing and assessment of neuropathic symptoms, vibration perception threshold (VPT), sudomotor function and corneal confocal microscopy (CCM) at baseline and follow‐up between 4 and 7 years.

Results

Of 76 participants, 69.7% were on glucose lowering medication associated with WG, and 30.3% were on glucose lowering medication associated with WL. At baseline, participants in the WG group had a significantly longer duration of diabetes ( p < .01), higher douleur neuropathique en 4 (DN4) score ( p < .0001) and VPT ( p = .01) compared with those in the WL group. Over a 56‐month period, participants in the WG group showed no significant change in body weight ( p = .11), HbA1c ( p = .18), triglycerides ( p = .42), DN4 ( p = .11), VPT ( p = .15) or Sudoscan ( p = .43), but showed a decline in corneal nerve fiber density (CNFD), corneal nerve branch density (CNBD) and corneal nerve fiber length (CNFL) ( p < .0001). Participants in the WL group showed a reduction in weight ( p = .01) and triglycerides ( p < .05), no change in DN4 ( p = .30), VPT ( p = .31) or Sudoscan ( p = .17) and a decline in the corneal nerve branch density ( p < .01).

Conclusions

Participants treated with glucose lowering medication associated with weight gain had worse neuropathy and greater loss of corneal nerves during follow‐up, compared to patients treated with medication associated with weight loss.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 2Diabetic NeuropathiesWeight LossHypoglycemic AgentsHumansMaleMiddle AgedFemaleAgedDisease ProgressionFollow-Up StudiesObesity

Stichwörter der Autor:innen

corneal confocal microscopydiabetic peripheral neuropathyglucose lowering medicationtype 2 diabetesweight change

Substanzen

Hypoglycemic Agents

Autor:innen und Institutionen

  • Department of Medicine, Weill Cornell Medicine-Qatar, Qatar Foundation, Doha, Qatar.
  • National Diabetes Center, Hamad General Hospital, Hamad Medical Corporation, Doha, Qatar.
  • Royal College of Surgeons in Ireland Bahrain, Adliya, Bahrain.
  • Division of Cardiovascular Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, UK.
  • Faculty of Science and Engineering, Manchester Metropolitan University, Manchester, UK.

ORCID-Profile: Georgios Ponirakis, Adnan Khan, Rayaz A Malik

Förderung

  • Qatar National Research Fund

Zitieren

APA

Ponirakis, G., Al-Janahi, I., Elgassim, E., Hussein, R., Petropoulos, I. N., Gad, H., Khan, A., Zaghloul, H. B., Siddique, M. A., Ali, H., Mohamed, F. F. S., Ahmed, L. H. M., Dakroury, Y., El Shewehy, A. M. M., Saeid, R., Mahjoub, F., Al-Thani, S. N., Ahmed, F., Homssi, M., …, & Malik, R. A. (2024). Glucose‐lowering medication associated with weight loss may limit the progression of diabetic neuropathy in type 2 diabetes. Journal of the Peripheral Nervous System, 29(4), 406-414. https://doi.org/10.1111/jns.12664

Vancouver

Ponirakis G, Al-Janahi I, Elgassim E, Hussein R, Petropoulos IN, Gad H, et al. Glucose‐lowering medication associated with weight loss may limit the progression of diabetic neuropathy in type 2 diabetes. Journal of the Peripheral Nervous System. 2024;29(4):406-414. doi:10.1111/jns.12664

BibTeX
@article{Ponirakis2024,
  author = {Ponirakis, Georgios and Al-Janahi, Ibrahim and Elgassim, Einas and Hussein, Rawan and Petropoulos, Ioannis N and Gad, Hoda and Khan, Adnan and Zaghloul, Hadeel B and Siddique, Mashhood A and Ali, Hamda and Mohamed, Fatima F S and Ahmed, Lina H M and Dakroury, Youssra and El Shewehy, Abeer M M and Saeid, Ruba and Mahjoub, Fadwa and Al-Thani, Shaikha N and Ahmed, Farheen and Homssi, Moayad and Mahmoud, Salah and Hadid, Nebras H and Obaidan, Aisha Al and Salivon, Iuliia and Mahfoud, Ziyad R and Zirie, Mahmoud A and Al-Ansari, Yousuf and Atkin, Stephen L and Malik, Rayaz A},
  title = {Glucose‐lowering medication associated with weight loss may limit the progression of diabetic neuropathy in type 2 diabetes},
  journal = {Journal of the Peripheral Nervous System},
  year = {2024},
  volume = {29},
  number = {4},
  pages = {406--414},
  doi = {10.1111/jns.12664}
}
Kostenlos starten →